Concepedia

Author

Takeshi Kitazaki

Nagasaki University

Also Known As

Hiroaki Senju, Hirofumi Nakano, Kitazaki T, T Kitazaki, T. Kitazaki, Takeshi KITAZAKI, Takeshi Kitazaki

66

Publications

1.6K

Citations

19

H-Index

29

Concepts

All Affiliations

Nagasaki UniversityJapanese Red Cross Society, JapanNagasaki University HospitalOita UniversityKawasaki Medical School
TK

About

Takeshi Kitazaki is an author at Nagasaki University specializing in medicine, oncology, and lung cancer.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

11

12

456

2

Pathology

9

9

230

3

Cell Biology

2

2

208

4

Immunology

2

2

68

5

Health Sciences

1

1

30

Takeshi Kitazaki

×

25

Publications

1.5K

Citations

18

H-Index

YearCitations

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells

Hirokazu Taniguchi, Tadaaki Yamada, Rong Wang,

Nature Communications

2019

351

Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells

Takeshi Kitazaki, Mikio Oka, Yoichi Nakamura,

Lung Cancer

2005

177

Gefitinib (“Iressa”, ZD1839), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses Breast Cancer Resistance Protein/ABCG2–Mediated Drug Resistance

Yoichi Nakamura, Mikio Oka, Hiroshi Soda,

Cancer Research

2005

177

Reversal of breast cancer resistance protein (BCRP/ABCG2)‐mediated drug resistance by novobiocin, a coumermycin antibiotic

Ken Shiozawa, Mikio Oka, Hiroshi Soda,

International Journal of Cancer

2003

119

ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in <i>EGFR</i> -Mutated Non–Small Cell Lung Cancer

Naoko Okura, Naoya Nishioka, Tadaaki Yamada,

Clinical Cancer Research

2020

108

Expression and functional analyses of breast cancer resistance protein in lung cancer.

Shigeru Kawabata, Mikio Oka, Hiroshi Soda,

PubMed

2003

94

The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells

Seiji Doi, Hiroshi Soda, Mikio Oka,

Molecular Cancer Therapeutics

2004

69

BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer

Seiji Nagashima, Hiroshi Soda, Mikio Oka,

Cancer Chemotherapy and Pharmacology

2006

41

Different effects of telithromycin on MUC5AC production induced by human neutrophil peptide-1 or lipopolysaccharide in NCI-H292 cells compared with azithromycin and clarithromycin

Hiroshi Ishimoto, Hiroshi Mukae, Noriho Sakamoto,

Journal of Antimicrobial Chemotherapy

2008

35

Spontaneous remission of a non-small cell lung cancer possibly caused by anti-NY-ESO-1 immunity

Yoichi Nakamura, Yuji Noguchi, Eiichi Satoh,

Lung Cancer

2009

34

Page 1